OBI Pharma Inc (台灣浩鼎) yesterday released the results of its second and third-phase clinical trials of a new breast cancer drug, OBI-822, saying the outcome of the study shows “no statistical significance.”
While the study did not meet the primary efficacy endpoint of progression-free survival (PFS), the results still contain “meaningful scientific and clinical information,” which have provided “clear direction for future product development,” the company said in a statement.
OBI Pharma chairman Michael Chang (張念慈) said the company has received valuable information from the clinical trials, such as a substantial improvement in the PFS rate of the treatment group who demonstrated an immune response to the vaccine, as well as a clear, positive trend in the secondary endpoint of overall survival for patients.
Photo: CNA
“This information is very important for designing the global third-phase study of the new drug,” Chang said in the statement.
OBI-822 is designed to target Globo H, an oligosaccharide tumor antigen, to trigger the immune system to generate antibodies that activate cytotoxic T cells to destroy cancer cells.
Industry observers have viewed the drug as a promising aid to active immunotherapy for metastatic breast cancer, with curative effects far better than Herceptin of Swiss pharmaceuticals maker Roche Holding AG and Ibrance of US pharmaceuticals firm Pfizer Inc.
Chinese-language monthly Wealth Magazine executive director Hsieh Chin-ho (謝金河) yesterday raised some questions about OBI Pharma.
“The market was waiting for the results of OBI Pharma’s phase two and three trials for OBI-822 today, but the outcome is worse than expected, as it did not pass clinical trials,” Hsieh wrote in a post on his Facebook page. “How seriously will the news affect the company’s shares? I am afraid it cannot be taken in so easily,” he wrote.
OBI Pharma, the most expensive stock in the biotech sector, closed at NT$681 on the Taipei Exchange in Friday trading, down 3.81 percent from the previous session. The stock rose 3.97 percent this year and surged by 119.7 percent from its listing price of NT$310 in March last year.
The fate of the shares of another drug company in 2014 might be a lesson for OBI Pharma shares, Hsieh said, referring to Medigen Biotechnology Corp (基亞).
In July 2014, Medigen Biotechnology Corp announced an interim study of its new liver cancer drug, PI-88, saying it did not yield positive results, which drove its shares down for 20 straight sessions by the maximum daily limit until it fell to NT$112.5 from NT$459.
The sell-off in Medigen spread to other biotech stocks, causing great losses to investors at the time, Hsieh said.
PERSISTENT RUMORS: Nvidia’s CEO said the firm is not in talks to sell AI chips to China, but he would welcome a change in US policy barring the activity Nvidia Corp CEO Jensen Huang (黃仁勳) said his company is not in discussions to sell its Blackwell artificial intelligence (AI) chips to Chinese firms, waving off speculation it is trying to engineer a return to the world’s largest semiconductor market. Huang, who arrived in Taiwan yesterday ahead of meetings with longtime partner Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), took the opportunity to clarify recent comments about the US-China AI race. The Nvidia head caused a stir in an interview this week with the Financial Times, in which he was quoted as saying “China will win” the AI race. Huang yesterday said
Japanese technology giant Softbank Group Corp said Tuesday it has sold its stake in Nvidia Corp, raising US$5.8 billion to pour into other investments. It also reported its profit nearly tripled in the first half of this fiscal year from a year earlier. Tokyo-based Softbank said it sold the stake in Silicon Vally-based Nvidia last month, a move that reflects its shift in focus to OpenAI, owner of the artificial intelligence (AI) chatbot ChatGPT. Softbank reported its profit in the April-to-September period soared to about 2.5 trillion yen (about US$13 billion). Its sales for the six month period rose 7.7 percent year-on-year
MORE WEIGHT: The national weighting was raised in one index while holding steady in two others, while several companies rose or fell in prominence MSCI Inc, a global index provider, has raised Taiwan’s weighting in one of its major indices and left the country’s weighting unchanged in two other indices after a regular index review. In a statement released on Thursday, MSCI said it has upgraded Taiwan’s weighting in the MSCI All-Country World Index by 0.02 percentage points to 2.25 percent, while maintaining the weighting in the MSCI Emerging Markets Index, the most closely watched by foreign institutional investors, at 20.46 percent. Additionally, the index provider has left Taiwan’s weighting in the MSCI All-Country Asia ex-Japan Index unchanged at 23.15 percent. The latest index adjustments are to
CRESTING WAVE: Companies are still buying in, but the shivers in the market could be the first signs that the AI wave has peaked and the collapse is upon the world Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reported a new monthly record of NT$367.47 billion (US$11.85 billion) in consolidated sales for last month thanks to global demand for artificial intelligence (AI) applications. Last month’s figure represented 16.9 percent annual growth, the slowest pace since February last year. On a monthly basis, sales rose 11 percent. Cumulative sales in the first 10 months of the year grew 33.8 percent year-on-year to NT$3.13 trillion, a record for the same period in the company’s history. However, the slowing growth in monthly sales last month highlights uncertainty over the sustainability of the AI boom even as
RSS